CAMKIIγ suppresses an efferocytosis pathway in macrophages and promotes atherosclerotic plaque necrosis
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Atherosclerosis is the underlying etiology of cardiovascular disease, the leading cause of death worldwide. Atherosclerosis is a heterogeneous disease in which only a small fraction of lesions lead to heart attack, stroke, or sudden cardiac death. A distinct type of plaque containing large necrotic cores with thin fibrous caps often precipitates these acute events. Here, we show that Ca2+/calmodulin-dependent protein kinase γ (CaMKIIγ) in macrophages plays a major role in the development of necrotic, thin-capped plaques. Macrophages in necrotic and symptomatic atherosclerotic plaques in humans as well as advanced atherosclerotic lesions in mice demonstrated activation of CaMKII. Western diet-fed LDL receptor-deficient (Ldlr-/-) mice with myeloid-specific deletion of CaMKII had smaller necrotic cores with concomitantly thicker collagen caps. These lesions demonstrated evidence of enhanced efferocytosis, which was associated with increased expression of the macrophage efferocytosis receptor MerTK. Mechanistic studies revealed that CaMKIIγ-deficient macrophages and atherosclerotic lesions lacking myeloid CaMKIIγ had increased expression of the transcription factor ATF6. We determined that ATF6 induces liver X receptor-α (LXRα), an Mertk-inducing transcription factor, and that increased MerTK expression and efferocytosis in CaMKIIγ-deficient macrophages is dependent on LXRα. These findings identify a macrophage CaMKIIγ/ATF6/LXRα/MerTK pathway as a key factor in the development of necrotic atherosclerotic plaques.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797
Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A., & Schwartz, S. M. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.5.1262 · Cited by 4,084
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
Serhan, C. N., Chiang, N., & Van Dyke, T. E. (2008) · Nature Reviews Immunology · doi:10.1038/nri2294 · Cited by 2,932
Macrophages in the Pathogenesis of Atherosclerosis
Moore, K. J., & Tabas, I. (2011) · Cell · doi:10.1016/j.cell.2011.04.005 · Cited by 2,669
Self-citationMacrophage death and defective inflammation resolution in atherosclerosis
Tabas, I. (2010) · Nature Reviews Immunology · doi:10.1038/nri2675 · Cited by 1,120
Self-citationPhagocytosis of apoptotic cells in homeostasis
Arandjelovic, S., & Ravichandran, K. S. (2015) · Nature Immunology · doi:10.1038/ni.3253 · Cited by 959
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis
Kojima, Y., Volkmer, J.-P., McKenna, K., Civelek, M., Lusis, A. J., Miller, C. L., Direnzo, D., Nanda, V., Ye, J., Connolly, A. J., et al. (2016) · Nature · doi:10.1038/nature18935 · Cited by 683 · cited 1×
“Defective efferocytosis can result if apoptotic cells resist uptake by phagocytes, as described recently for atherosclerosis (38), or if the phagocytes themselves have an impairment in apoptotic cell binding or internalization.”
BackgroundPathophysiology of native coronary, vein graft, and in-stent atherosclerosis
Yahagi, K., Kolodgie, F. D., Otsuka, F., Finn, A. V., Davis, H. R., Joner, M., & Virmani, R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.164 · Cited by 548 · cited 2×
“org Volume 127 Number 11 November 2017 Discussion The development of large necrotic cores with thin overlying collagen caps is a hallmark of a particular type of human plaque that can trigger acute thrombo-occlusive vascular events (5, 21).”
BackgroundPhagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis
Schrijvers, D. M., De Meyer, G. R. Y., Kockx, M. M., Herman, A. G., & Martinet, W. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000166517.18801.a7 · Cited by 509 · cited 1×
“Studies have shown that macrophage-mediated efferocytosis is defective in advanced human plaques that have not yet ruptured (7, 8).”
BackgroundLi, Y., Schwabe, R. F., DeVries-Seimon, T., Yao, P. M., Gerbod-Giannone, M.-C., Tall, A. R., Davis, R. J., Flavell, R., Brenner, D. A., & Tabas, I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501759200 · Cited by 421
Self-citation
Cited by
Efferocytosis in health and disease
Doran, A. C., Yurdagul, A., & Tabas, I. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0240-6 · Cited by 1,066
Self-citationTargeting inflammation in atherosclerosis — from experimental insights to the clinic
Soehnlein, O., & Libby, P. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00198-1 · Cited by 1,019
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
Chen, W., Schilperoort, M., Cao, Y., Shi, J., Tabas, I., & Tao, W. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00629-x · Cited by 518
Self-citationDrugging the efferocytosis process: concepts and opportunities
Mehrotra, P., & Ravichandran, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00470-y · Cited by 459
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?
Engelen, S. E., Robinson, A. J. B., Zurke, Y.-X., & Monaco, C. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00668-4 · Cited by 425
The role of non-resolving inflammation in atherosclerosis
Kasikara, C., Doran, A. C., Cai, B., & Tabas, I. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97950 · Cited by 266
Self-citationGui, Y., Zheng, H., & Cao, R. Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.845942 · Cited by 258
Tao, W., Yurdagul, A., Kong, N., Li, W., Wang, X., Doran, A. C., Feng, C., Wang, J., Islam, M. A., Farokhzad, O. C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1063 · Cited by 255
Self-citationCai, B., Kasikara, C., Doran, A. C., Ramakrishnan, R., Birge, R. B., & Tabas, I. (2018) · Science Signaling · doi:10.1126/scisignal.aar3721 · Cited by 175
“Furthermore, myeloid cell–specific deletion of Camk2g led to an increase in cell-surface MerTK through a pathway involving induction of the Mertk inducer, liver X receptor (LXR) (59).”
InfluentialSelf-citationMonocytes and macrophages as protagonists in vascular complications of diabetes
Kanter, J. E., Hsu, C.-C., & Bornfeldt, K. E. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00010 · Cited by 76
Metadata
- Authors
- Doran, A. C., Ozcan, L., Cai, B., Zheng, Z., Fredman, G., Rymond, C. C., Dorweiler, B., Sluimer, J. C., Hsieh, J., Kuriakose, G., Tall, A. R., & Tabas, I.
- Venue
- Journal of Clinical Investigation
- Published
- 2017-10-03
- Volume
- 127
- Issue
- 11
- Pages
- 4075-4089
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2763821973
- Cited by
- 112
- References
- 19
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.